Jonakayem Pharma Formulation (OPC) Pvt. Ltd.


Send Inquiry

Formulary: Generic Formulary
Category: Endocrine System
International Brand Name: Kenolog,Aristocort, Nasacort, Tri-Nasal, Treiderm,Azmacort, Trilone,Volon A, Tricorlone, Triensence
Dosages: 4 MG/10 MG/ML/40ML/ML
Unit of Packing: Tablets
In treatment of: Replacement therapy in Adrenal insufficiency

Adverse Effects: 

  • Susceptibility to infection
  • Peptic ulcer
  • Haemorrhage Glycosuria
  • Hyperglycaemia
  • Osteoporosis
  • Atrophy of adrenal cortex(on prolonged therapy)
  • Suppression of adrenocorticotropic hormone
  • Cushing`s syndrome
  • Inhibition of growth in children
  • Amenorrhoea
  • Behavioral disturbances
  • Thromboembolic disorders
  • Myopathy
  • Weakness
  • Lymphocytopenia
  • Muscle wasting
  • Gastrointestinal discomfort
  • Increased appetite
  • Delayed wound healing
  • Headache
  • Euphoria
  • Insomnia
  • Seizures
  • Heart failure
  • Arrhythmias
  • Posterior sub capsular cataract
  • Glaucoma
  • Sodium and fluid retention
  • Hypo kalaemia
  • Increased intracranial pressure


  • Hypersensitivity to the drug
  • Epilepsy
  • Peptic ulcer
  • Tuberculosis
  • Systemic fungal infections
  • Herpes simplex
  • Renal impairment
  • Not to be given intravenously

Special Precaution: 

  • Avoid sudden discontinuation of the drug
  • Monitor vital parameters, therapeutic response and adjust the dosage
  • Use lower dosages as much as possible
  • Osteoporosis
  • Primary glaucoma
  • Primary psychosis and psychoneurosis
  • Recent myocardial infarction
  • Heart failure
  • Diabetes mellitus
  • Hypothyroidism
  • Cirrhosis
  • Stress
  • Sepsis
  • Hypertension
  • Myasthenia gravis
  • Hepatic impairment
  • Non specific Ulcerative colitis
  • Diverticulitis
  • Recent intestinal anastomosis
  • Seizures
  • Thromboembolic disorders

Interaction: Barbiturates: Decreases efficacy of triamcinolone. Oral contraceptives: May increase half life and concentration of triamcinolone. Oestrogens: May decrease clearance of triamcinolone. Rifampicin: Decreases efficacy. Triamcinolone effects the action of the following: Anticiholinesterases: Efficacy antagonised in myasthenia gravis. Oral anticoagulants: Altered response. Cyclosporine: Increased cyclosporine efficacy, toxicity may be enhanced. Digitalis glycosides: Increased possibility of toxicity associated with hypokalaemia. Isoniazid: Decreased serum levels of isoniazid. Salicylates: Decreased serum levels of salicylates. Diuretics: May cause increased hypokalaemia and increased hyperglycemia. Non-depolarising muscle relaxants: Altered response. Theophyllines: Altered response of either agent. Lab Tests: Increases serum cholesterol levels. Increases urine glucose levels. Decreases Thyroid I uptake. Decreases T3 serum levels. Decreases serum potassium.

Servings: Oral: 4 to 32mg/day as once daily or 2 to 4 divided doses depending up on the severity of the condition. Children: 4 to 12mg/day Adrenal insufficiency: 4 to 12mg/day as once daily or as divided doses depending up on the severity of the condition. Children: 117mcg/kg/day as once daily or as divided doses. Collagen diseases, Tuberculous meningitis: 30 to 48mg/day. Respiratory diseases: 16 to 48mg/day as once daily or as divided doses depending up on the severity of the condition. Malignancies: 16 to 100mg/day as once daily or as divided doses depending up on the severity of the condition. Parenteral: 4 to 32mg/day as once daily or as divided doses I.M.: 40 to 60mg as deep I.M. injection depending up on the severity of the condition. In asthma and hey fever increases the dosage up to 100mg as required by the patient. Intra-articular: 2.5mg to 15mg depending up on the severity of the condition. Intradermal: 0.2 to 0.3ml